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Regression of renal cyst in a NSCLC patient treated with crizotinib
Dear Editor,
Crizotinib is one of the therapeutic agents for 
patients with ALK fusion gene mutated non-small 
cell lung cancer [1–5]. With crizotinib therapy, pa-
tients who develop renal cysts have been reported 
[1–5]. It is well-known that there were patients 
whose renal cyst had shrunk after discontinu-
ation of crizotinib or change to alectinib [1–3]. 
Recently we experienced a patient whose renal 
cyst shrank despite continued treatment with cri-
zotinib which achieved a good therapeutic effect. 
We would like to share our experience. 
A 38-year-old man referred to our hospital due 
to abnormal opacity in chest radiograph in mass 
screening. Since mediastinal lymph node lesions 
were confirmed during the operation, left pneumo-
nectomy with nodal dissection was performed. The 
final pathological diagnosis was adenocarcinoma 
and pathological tumor stage was proved to be 
T1bN2M0. Fluorescence in situ hybridization of the 
resected specimen revealed a translocation of ALK. 
On CT scan taken 27 months after the pneumonec-
tomy, a nodule of the left adrenal gland was found, 
and the patient started to receive crizotinib. On CT 
scan taken 5 months after the initiation of crizoti-
nib, a cyst was found in the right kidney (Figure 
1A). The patient was explained the results of the 
consultation with the urologist, but he preferred 
to continue this treatment. Crizotinib therapy was 
Figure 1. CT taken: A. 5 months; B. 8 months; C. and 17 months after initiation of crizotinib therapy
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continued and the patient was carefully followed 
up. CT scan performed 8 months and 17 months 
after initiation of crizotinib therapy confirmed 
shrinkage of the cyst. There was no enlargement in 
cysts on CT performed one year after the shrinkage 
had been confirmed (Figures 1B, 1C). 
Spontaneous regression and shrinkage of the 
renal cyst without discontinuation of crizotinib 
occurred [4, 5]. We experienced a patient whose 
renal cysts shrank despite continued treatment 
with crizotinib. Rare and careful follow-up is 
necessary, however, if the effect of crizotinib is 
sustained, the continuation of the drug may be 
one of the treatment options.
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